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Abstract: 
Photodynamic therapy (PDT) is a treatment that uses special drugs called 
photosensitizing agents along with light to kill cancer cells. The specialized drugs only 
work after they have been activated or "turned on" by light. Photodynamic therapy may 
also be called photoradiation therapy, phototherapy, or photochemotherapy. In this 
research, I focused on the addition of foUl' separate hydroxyl~amines to the unsubstituted 
porphyrin core, H2TPPC. The hydroxyl~amines attached to the porphyrin core were 5~ 
amino-1-pentanol, 2-amino-2-ethyl-1 ,3-propanediol,3-amino-propanediol, and 5-
aminovaleric acid. The novel water soluble PDT agents, H2TPP-ASOH, H2TPP-2Ef, 
H2TPP-3NH, and lhTPP-SAV, which were synthesized and purified, was structurally 
characterized by infrared spectroscopy (IR), nuclear magnetic resonance 
spectroscopy(NMR), and UV ~vis spectroscopy. The purity of the compounds were 
confirmed through analyzing using high perfonnance liquid chromatography (HPLC). 
Finally, the cytotoxicity of the novel PDT porphyrins were detennined in the presence 
and absence of light using MTT assay on MDA-MB-231 triple negative breast cancer 
cells and Ewing's Sarcoma cells. 
Introduction 
Although PTD is a relatively new treatment, a method of treating diseases with 
light can be traced far back in history. The ancient Egyptians utilized a combination of 
orally ingested plants containing light-activated psoralens and sunlight to treat diseases 
over 4,000 years ago. Contemporary photodynamic therapy began in 1900 with Oscar 
Raab and Hennann von Tappeiner. While in research, the two men noticed paramecia, 
that had been incubated with the dye, died when exposed to sunlight from an adjacent 
window .1 From the time of this discovery, investigations were made to develop light 
therapy that would aid in killing cancer cells. Photodynamic therapy requires 
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photosensitizing agents paired with specific amounts of light to decrease cancerous cells. 
The photosensitizing agents are molecules that produce reactive oxygen species that are 
activated when illuminated with light. When the molecules are exposed to the specific 
light source, they release oxygen that kills nearby cells. These are activated by specific 
wavelengths of light. The wavelength of light determines the depth the light penetrates 
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into the tissue. The photosynthesizing agents are injected directly into the bloodstream 
and the photosensitizing agents are absorbed into most cells throughout the body, but 
remain absorbed in only the cancer cells after a period between twenty-four and seventy-
two hours. Therefore, photosensitizers have a higher cellular uptake in cancer cells over 
normal cells. When most of the agent has exited normal cells but remains in cancerous 
cells, the tumor is then exposed to the correct amount of light. The photosensitizer in the 
tumor absorbs the light and produces oxygen that destroys the nearby cancer cells. Along 
with directly killing the cancer cells, the photosensitizer may also damage nearby blood 
vessels preventing the cancerous tumor from receiving essential nutrients. Therefore PDT 
does not have the harmful side effects often encountered with chemotherapy or radiation 
therapy. 
Porphyrin derivatives are the most common photosensitizing agent used in PDT. 
A porphyrin consists of four interconnected pyrrole rings making it an aromatic structure. 
Many porphyrins are naturally occurring. A well-known porphyrin is heme (Figure 1) 
which is a cofactor in hemoglobin. The ability of red light to penetrate tissue better than 
light of other wavelengths is a desired characteristic of photosensitizing agents for 
targeting cancer cells. 
Breast cancer is divided into subgroups and distinguished by presence and 
appearance of the tumor based on a histological classification system. This histological 
classification system includes subgroups based on lymph node involvement, tumor size, 
and distant metastasis occurrence. Characteristics such as stage, grade, and receptor 
status help identifY the type of breast cancer. The type of breast cancer used throughout 
this research was the subgroup l\IDA-MB-231 triple negative breast cancer. This 
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subgroup lacks the presence of three main receptors: estrogen receptor (ER), progesterone 
receptor (PR), and human epidermal growth factor receptor (HER2).2 Unfortunately, 
treatments such as chemotherapy and radiotherapy target a combination of these receptors 
making triple negative breast cancer a difficult subgroup to treat. About fifteen percent of 
breast cancer patients are diagnosed with triple negative breast cancer. This subgroup 
proves to be more common in younger women. 1 The specific prognosis depends on the 
stage of the cancer, but the cancer is aggressive and highly likely to reoccur throughout 
the body. Because of the percentage rate, aggression, and reoccurrence, triple negative 
breast cancer was chosen for this research. Photodynamic therapy does not target specific 
receptors; the therapy pairs with light to diminish the cancerous cells making this a great 
method of treatment for triple negative breast cancer. Triple negative breast cancer was 
also chosen for this research because of its location on the body. Photodynamic therapy 
is known to be limited to areas where light can reach. This treatment option is 
prominently used to treat affected areas on the skin or in the case of this research, just 
under the skin. To detetmine if PTD was strictly limited to areas easily penetrated by 
light, this research also included trial runs with Ewing's Sarcoma. 
Figure 1. 
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Methods 
H2TPPC (Figure 2) was synthesized by combining a pyrrole with 4-fonnyl 
benzoic acid then undergoing an acid chloride formation (Figure 3). Once the acid 
chloride ofH2TPPC was synthesized, an additional side-chain was added to create the 
desired porphyrin (Figure 4). The side chain determined which porphyrin would be 
synthesized. In this research, all porphyrins were synthesized alike with the exception of 
the different side chains being adding onto the H2TPPC. Figures 4-6 display the different 
porphyrins synthesized in this research. Before applying the porphyrin to either type of 
cancer cells within this research, a series of characterization steps were completed to 
correctly identify the desired porphyrin. After synthesizing the novel water-soluble 
porphyrin, before characterization, the porphyrins were purified through a series of two 
columns, Sephadex G-50 and Sephadex LH-20. The brown liquid exiting the column 
was discarded until it turned purple. After this moment, the eluent was collected then 
dried by using a roto-vap within the laboratory. This procedure was done two different 
times to ensure purity. The characterization steps were critical in this research. The 
porphyrin was first characterized by infrared spectroscopy. Infrared spectroscopy (IR 
spectroscopy) was used to identify certain peaks found within the lR spectrum. Prior to 
running the porphyrin using theIR spectrometer, the original amine was characterized to 
serve as a parallel example. The amine and the porphyrin, because of correct 
characterization, portrayed similar peaks on each absorption spectrum. 
A calculated concentration ofthe porphyrin was placed into an Ultraviolet-visible 
spectrometer. Ultraviolet-visible spectroscopy (UV -vis) refers to the absorptions 
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spectroscopy in the ultraviolet-visible spectral region. Porphyrins are characterized by 
the presence of an intense UV -vis band at approximately 415nm called the So ret band. 
Using Beer's Law, the specific absorption of the porphyrin was calculated. Beer's Law 
also aided in calculating the appropriate concentration of the porphyrin needed to put into 
the cell plate for MTT assay. 
The porphyrin was then characterized by nuclear magnetic resonance 
spectroscopy. Nuclear magnetic resonance spectroscopy (NMR spectroscopy) is a 
technique that allows characterizations of organic molecules. Again, the original amine 
was tested to provide a comparison to that of the desired porphyrin material. The graphs 
of the porphyrin displayed prope11ies of the otiginal amine proving that the porphyrin was 
conectly characterized. 
After each characterization of the porphyrin was complete, the purity of the 
compound was analyzed through high performance liquid chromatography. High 
performance liquid chromatography (HPLC) is a highly improved form of column 
chromatography like previously used in this research. The solvent is forced through the 
column under high pressures making this technique much faster than column 
chromatography. A much smaller particle size for the column packing material is utilized 
which allows a greater surface area for interactions between the stationary phase and the 
molecules moving through it. This technique gives a much better separation of the 
components, which is why the HPLC technique was used to determine the purity of the 
compound. Having a porphyrin purity no less than 97% pure, the porphyrin was now 
ready to be placed into the cell plate. 
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Prior to applying the prepared porphyrin into the cell plate, the cell plate needed 
preparation. After the cancer cells were cultured in medium, the cells were injected into 
two parallel 96-well plates. Appropriate concentrations of the porphyrins were injected 
into the cells approximately 72 hours after plating. The calculated concentrations were 
l J,.l.M, 3J,.l.M, l OJ..lM, 30J..1.M, and 1 OOJ..lM. The plates were prepared in duplicated to test 
under both light and dark conditions. One plate was exposed to light for approximately 
15 minutes 24 hours after the porphytin was added. During this time, the parallel plate 
was kept in complete darkness. Tbree days after the exposw·e to light, the cytotoxicity of 
the porphyrins were assayed using MTT assay. 
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Figure 7 is the UV-vis Spectroscopy graph of the porphyrin H2TPP~ASOH in H20. This 
graph showed the absorbance of a typical porphyrin at the peak located at 4.15nm. Beside 
the graph is the table used to conduct Beer's law in order to caJculate the desi red 
concentration of porphyrin to be injected into the different cancer cells. 
Figw·e 8. 
Figure 8 is the UV-vis spectroscopy graph of the porphyrin H2TPP-2ET in H20. 
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Figure 9. 
Figure 9 is the UV-vis spectroscopy graph of the porphyrin H2TPP-3NH. 
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Figure 10. 
Figure 10 is the UV -vis spectroscopy graph of the porphyrin H2TPP-SA V. 
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Figure 11 is the JR Spectroscopy graph of the porphyrin H2TPP-ASOH. This graph 
shows the peaks of both the original amine as well as the porphyrin core which 
characterized the porphyrin as H2TPP-ASOH. 
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Figure 12 is theIR spectroscopy graph of HzTPP-2ET. 
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Figure 13 is the IR spectroscopy graph of H2 TPP-3NH 
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Figure 14. 
Figure 14 is the graph ofthe IR spectroscopy ofH2TPP-SAV. 
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Figure 16. 
Both figure 15 and figure 16 are NMR spectroscopy graphs. Figure 15 represents the 
NMR spectroscopy graph of the attached amine, 5-amino-1-pentanol. Figure 16 
represents the NMR spectroscopy graph of the synthesized porphyrin, H2TPP-ASOH. 
Having the figures parallel to one another presents a clear representation that the correct 
porphyrin was synthesized. The peaks of each graph are identical as desired. In figure 
16, there are two new peaks which are characteristic of a porphyrin. 
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Figure 17. 
Figure 17 is the NMR spectroscopy graph ofH2TPP-2ET. 
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Figure 18 is the NMR spectroscopy graph ofH2TPP-3NH. 
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Figure 19 is the NMR spectroscopy graph ofH2TPP-SAV. 
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Purity: 98% 
Waters Nova-Pak Cl8 
3.9 x 150 mm column 
u Solvent: 100% Acetonitrile 
Flow Rate: 1.00 mL/min 
Figure 20 is a graph of the HPLC test. After characterization of the porphyrin, the purity 
was analyzed through high performance liquid clu·omatography. The purity of 
H2TPPASOH was 98% pure which allowed the porphyrin to be prepared to be injected 
into the cancer cells. 
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Figure 21 is a graph ofthe HPLC test conducted on H2TPP-3NH. 
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Figure 22. 
Figure 22 is a graph of the HPLC test conducted on H2TPP-SAV. 
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Figure 23 is a graph ofthe MTT assay results ofH2TPP-ASOH injected into MD-MB-231 
triple-negative breast cancer cells. The graph includes the results from both the 96-well plate 
exposed to light and the 96-well plate kept in darkness. The results show a greater cell death 
in those cells exposed to light. 
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Fi,brure 24 is a graph of the MTT assay results of Ih TPP-2ET into MD-MB-231 triple breast cancer 
cells. 
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Figure 25 is a graph of the MTT assay results of H2 TPP-3NH injected into MD-MB-231 
triple negative breast cancer. 
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Figure 26 is a graph oftheMTI assay results ofH2TPP-ASOH injected into Ewings 
sarcoma cells. 
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Figure 27 is a graph of the MIT assay results of HzTPP-2ET injected into Ewings 
sarcoma cells. 
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Figure 28 is a graph of the MTT assay results offu.TPP-3NH injected into Ewings 
sarcoma cells. 
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Conclusion 
Throughout this research, a series of novel water-soluble porphyrins were 
synthesized and purif'icd. Characterizations of the compounds were determined through 
infrared spectroscopy, nuclear magnetic spectroscopy, and ultraviolet-visible 
spectroscopy. The spectrums not only identified the correct compow1d, but also exhibited 
the purity of the compound. At b'Tcatcr than 98% pure, the porphyrin identified was then 
used as a photosynthesi?.ing agent with MDA-M.B-231 triple-negative breast cancer cells 
and Ewings Sarcoma cells. MIT assay was prefonned to achieve the result·s. At a 
concentration of 60f..l.M to 1 OOfJ.M, cytotoxicity becomes evident. This research proves 
that photodynamic therapy could treat triple negative breast cancer celJs at a high 
concentration of 60).lM to l OOJ..!.M. Unfortw1ately, this concentration is rather high and 
could be detrimental to the human body. To improve this portion of the research, a 
different hydroxyl amine should be added onto the porphyrin core structure in order to 
alter the characteristics of the compound. Cytotoxicity at a low concentration is desired 
for the best possible results with triple negative breast cancer cells. With Ewings 
sarcoma cells, this research would need further advancement because the cell viability 
percentage was high no mRtter the concent1·ation of the synthesized porphyrins. With 
further research, photodynamic therapy has the potential to diminish tumors in the body 
without harmful side effects. 
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